RxDoctor Payments Data

Ramon Pimentel, MD

Internal Medicine · Jackson Heights, NYNPI 1033147426

Payments from drug & device makers

$1,916in general payments, 2019–2025

Across 96 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$521
  • Boehringer Ingelheim$312
  • Novo Nordisk$271
  • Amarin Pharma, Inc.$212
  • AbbVie$148
  • Lilly USA, LLC$121
  • plus $332 from 7 others

What the payments were for

  • Food & beverage$1,916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,916 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$23,361
Medicare patients
44
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin251$268,957
OzempicSemaglutide80$85,416
RybelsusSemaglutide50$74,711
JanumetSitagliptin Phos/Metformin Hcl31$34,751
JanuviaSitagliptin Phosphate33$29,359
EntrestoSacubitril/Valsartan19$24,993
LinzessLinaclotide36$23,391
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$17,641
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,258
Tresiba Flextouch U-100Insulin Degludec17$12,631
SynjardyEmpagliflozin/Metformin Hcl12$10,162
Breo ElliptaFluticasone/Vilanterol13$7,479
Diclofenac Sodium94$6,037
Atorvastatin Calcium307$2,938
Albuterol Sulfate HfaAlbuterol Sulfate52$2,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$312$279,118263 claims
Novo NordiskOzempic, Rybelsus$271$160,127130 claims
NovartisEntresto$112$24,99319 claims
AbbVieLinzess$148$23,39136 claims
GSKTrelegy Ellipta, Breo Ellipta$18$20,73724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jackson Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →